Life Cycle Investment Partners Ltd Makes New $30.71 Million Investment in Elevance Health, Inc. $ELV

Life Cycle Investment Partners Ltd bought a new position in Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 87,604 shares of the company’s stock, valued at approximately $30,710,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jefferies Financial Group Inc. increased its position in shares of Elevance Health by 498.0% during the 4th quarter. Jefferies Financial Group Inc. now owns 78,397 shares of the company’s stock worth $27,482,000 after purchasing an additional 65,288 shares during the last quarter. Americana Partners LLC increased its position in shares of Elevance Health by 2.7% during the 4th quarter. Americana Partners LLC now owns 1,249 shares of the company’s stock worth $438,000 after purchasing an additional 33 shares during the last quarter. LSV Asset Management increased its position in shares of Elevance Health by 464.7% during the 4th quarter. LSV Asset Management now owns 46,664 shares of the company’s stock worth $16,358,000 after purchasing an additional 38,400 shares during the last quarter. Keudell Morrison Wealth Management acquired a new stake in shares of Elevance Health during the 4th quarter worth about $1,764,000. Finally, Wilian Securities LLC acquired a new stake in shares of Elevance Health during the 4th quarter worth about $379,000. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $394.41 on Friday. The business has a 50-day moving average of $333.81 and a 200 day moving average of $336.25. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $408.00. The stock has a market capitalization of $85.65 billion, a price-to-earnings ratio of 16.78, a price-to-earnings-growth ratio of 2.23 and a beta of 0.66. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period last year, the business posted $11.97 EPS. Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, sell-side analysts forecast that Elevance Health, Inc. will post 26.91 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Analysts Set New Price Targets

ELV has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Jefferies Financial Group cut their price objective on Elevance Health from $395.00 to $391.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Bank of America raised Elevance Health from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $405.00 to $435.00 in a research report on Wednesday, April 29th. Barclays raised their price objective on Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a research report on Friday, April 24th. Finally, Mizuho raised their price objective on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and an average price target of $399.32.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.